Advanced in Chronic Granulomatous Disease

Ambroise Marcais

149, Rue De Sèvres, 
Paris, FR 
Advanced in Chronic Granulomatous Disease
149, Rue De Sèvres, 
Paris, FR 
OverviewLocationsClinical Research

Overview

Ambroise Marcais practices in Paris, France. Marcais is rated as an Advanced expert by MediFind in the treatment of Chronic Granulomatous Disease. Their top areas of expertise are Adult T-Cell Leukemia, Chronic Granulomatous Disease, T-Cell Lymphoma, Leukemia, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 86 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Chronic Granulomatous Disease.

Locations

149, Rue De Sèvres, Paris, 75015, France
Other Locations
L'Hôpital Pontchaillou, CHU de Rennes
Rennes, France
Creteil, France
France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.
Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.
Enrollment Status: Completed
Publish Date: July 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

86 Total Publications

Immunochemotherapy for older patients with ATLL: a new option?
Immunochemotherapy for older patients with ATLL: a new option?
Journal: Blood
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Marcais's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile